Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: ADMA - http://www.admabiologics.com/

No earlier versions found for this Subject.

Return to ADMA - http://www.admabiologics.com/

ADMA Biologics - admabiologics.com

A late-stage bio-pharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases. Targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons. Product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients with or at risk for certain infectious diseases.

ADMA also operates ADMA BioCenters, a FDA-licensed source plasma collection facilities which provide a portion of blood plasma for the manufacture of the Company's lead product candidate RI-002.

___________________________________________

WELCOME! —This is a moderated board. No spam, ad hominem attacks or flaming. One warning. Next time you're out, with your posts deleted.